Clinical Trial: NCT03105336
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Kite, A Gilead Company |
| Information Provided By: | Gilead Sciences |
| Last Update Posted: | 2025-12-23 |
Study Overview
Brief Summary
The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.
Official Title
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
Intervention / Treatment
- Biological: Axicabtagene ciloleucel
- Drug: Cyclophosphamide
- Drug: Fludarabine
Other Study ID Numbers
- KTE-C19-105
- 2017-001912-13
- 2023-505169-10
- 2023
- 2017
Start Date (Actual)
2017-06-06
Primary Completion Date (Actual)
2024-12-20
Study Completion Date (Actual)
2024-12-20
Enrollment (Actual)
159
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Kite, A Gilead Company |
| Information Provided By: | Gilead Sciences |
| Last Update Posted: | 2025-12-23 |
Study Overview
Brief Summary
The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.
Official Title
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
Intervention / Treatment
- Biological: Axicabtagene ciloleucel
- Drug: Cyclophosphamide
- Drug: Fludarabine
Other Study ID Numbers
- KTE-C19-105
- 2017-001912-13
- 2023-505169-10
- 2023
- 2017
Start Date (Actual)
2017-06-06
Primary Completion Date (Actual)
2024-12-20
Study Completion Date (Actual)
2024-12-20
Enrollment (Actual)
159
Study Type
Interventional
Phase
Phase 2